

IN THE CLAIMS:

Please amend the claims as follows:

1. (canceled)
2. (canceled)
3. (canceled)
4. (canceled)
5. (canceled)
6. (canceled)
7. (canceled)
8. (canceled)
9. (canceled)
10. (canceled)
11. (canceled)
12. (canceled)
13. (canceled)
14. (canceled)
15. (canceled)
16. (canceled)
17. (currently amended) An anti pneumococcal pharmaceutical composition comprising:
 - (a) a combination of the therapeutically effective amidase ~~anti-pneumococcal~~ lytic enzyme Pal obtained from bacteriophage and the muramidase ~~anti-pneumococcal~~ lytic enzyme Cpl-1 obtained from bacteriophage, wherein said Pal and Cpl-1 are each present at 0.5 minimal inhibitory concentration (MIC) or less and the combination demonstrates synergy as defined as a pneumococcal bacterial titer reduction of the combination of at least $\geq 2 \log_{10}$ greater than the pneumococcal bacterial titer reduction of the single Pal or Cpl-1 agents at the same concentration; and

(b) a carrier suitable for delivery of the lytic enzymes to the site of infection.

18. (canceled)

19. (canceled)

20. (canceled)

21. (canceled)

22. (canceled)

23. (currently amended) An anti-microbial composition for sanitizing or decontaminating porous or non-porous surfaces suspected of containing *Streptococcus pneumoniae* comprising a combination of the amidase ~~anti-pneumococcal~~ lytic enzyme Pal obtained from bacteriophage and the muramidase ~~anti-pneumococcal~~ lytic enzyme Cpl-1 obtained from bacteriophage, wherein Pal and Cpl-1 are each present at 0.5 minimal inhibitory concentration (MIC) or less and the combination demonstrates synergy as defined as a *Streptococcus pneumoniae* bacterial titer reduction of the combination of at least $\geq 2 \log_{10}$ greater than the *Streptococcus pneumoniae* bacterial titer reduction of the single Pal or Cpl-1 agents at the same concentration.

24. (canceled)

25. (canceled)

26. (canceled)

27. (canceled)

28. (canceled)

29. (canceled)

30. (currently amended) An anti pneumococcal pharmaceutical composition comprising:
(a) a combination of the amidase ~~anti-pneumococcal~~ lytic enzyme Pal obtained from bacteriophage and the muramidase ~~anti-pneumococcal~~ lytic enzyme Cpl-1 obtained from bacteriophage, comprising a mixture of Pal and Cpl-1 each at a concentration of 0.5 U/ml wherein the pneumococcal killing efficacy of the mixture is increased by

greater than 1 log₁₀ compared to 1 U/ml of Pal or Cpl-1 alone ; and

(b) a carrier suitable for delivery of the lytic enzymes to the site of infection.

31. (currently amended) An anti-microbial composition for sanitizing or decontaminating porous or non-porous surfaces suspected of containing *Streptococcus pneumoniae* comprising a combination of the amidase ~~anti-pneumococcal~~ lytic enzyme Pal obtained from bacteriophage and the muramidase ~~anti-pneumococcal~~ lytic enzyme Cpl-1 obtained from bacteriophage, comprising a mixture of Pal and Cpl-1 each at a concentration of 0.5 U/ml wherein the *Streptococcus pneumoniae* killing efficacy of the mixture is increased by greater than 1 log₁₀ compared to 1 U/ml of Pal or Cpl-1 alone.